Recent trials investigating the efficacy of this first‐line immune checkpoint inhibition for recurrent and/or metastatic HNSCC showed that PD‐L1 expression is associated with an increased objective response rate in patients with a combined positive score (CPS) of ≥1, with a better response being seen when the CPS was ≥20.9, 10. The gene discussed is CD274; the disease is head and neck squamous cell carcinoma.